High Quality Imatinib Mesylate for Antitumor CAS 220127-57-1

Product Description
High Quality Imatinib Mesylate for Antitumor CAS 220127-57-1

  • Model NO.: CAS 220127-57-1
  • Customized: Non-Customized
  • Suitable for: Elderly, Adult
  • Purity: >99%
  • Alias: Imatinib Mesylate
  • Molecular Formula: C30h35n7o4s
  • Appearance: White Powder
  • Usage: Pharmaceutical Raw Material
  • Trademark: sendi
  • Specification: steorids
  • HS Code: 3001200090
  • Powder: Yes
  • Certification: GMP, ISO 9001, USP, BP
  • State: Solid
  • Name: Imatinib Mesylate
  • CAS: 220127-57-1
  • Molecular Weight: 589.71
  • Garde: USP
  • MOQ: 10g
  • Transport Package: Discreet Pakage
  • Origin: Shenzhen
Product Description
Quick detail

Product Name:Imatinib Mesylate
CAS:220127-57-1
MF:C30H35N7O4S
MW:589.71
Assay:99%min
Appearence:White powder
Drug category:Anti tumor drug
Purpose:A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL).
Package:1kg/bag

Product Description

Imatinib mesylate is a tyrosine kinase inhibitor IC50 value of 100 nM, 100 nM, 600 nM for v-Abl, c-kit, PDGFR, respectively [1].

Imatinib Mesylate is a specific tyrosine kinase (abl, c-kit, and PDGFR) inhibitor and is reported to sensitize cells to radio- or chemo-therapy. When tested with Y-79 and WERI-RB-1 Rb cell lines, imatinib mesylate treatment decreased the cell proliferation and invasion with the concentration of 10 μM [3]. In osteoblast cells, administration of imatinib mesylate decreased osteoclast development via stimulating differentiation, inhibiting proliferation and survival [4].
In dog model with mast cell tumor, administration of imatinib mesylate at a dose of 10 mg/kg daily for 1-9 weeks reduced tumor growth via inhibiting tyrosine kinase [5].

Author: chemicals

Here is chemical sourse

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s